Update on Coccidioidomycosis in the United States and Beyond

Area of Science:

• Mycology
• Infectious Diseases
• Epidemiology

Background:

• Coccidioidomycosis is a significant fungal infection endemic to the western United States, Central America, and South America.
• Acquired through inhalation, it affects all age groups, with peak incidence following dry summers after wet winters.
• While often asymptomatic, it can manifest as influenza-like illness, pneumonia, or disseminated disease.

Purpose of the Study:

• To review the epidemiology, clinical presentation, diagnosis, and treatment of coccidioidomycosis.
• To highlight diagnostic methods and current therapeutic strategies.
• To discuss prevention and management in high-risk individuals.

Main Methods:

• Literature review of coccidioidomycosis epidemiology and clinical data.
• Analysis of diagnostic approaches, primarily serology.
• Evaluation of current antifungal treatment guidelines, focusing on azole therapies.

Main Results:

• The majority of coccidioidomycosis infections are asymptomatic.
• Symptomatic cases range from self-limiting influenza-like illness to severe pneumonia and disseminated disease.
• Serology is the primary diagnostic tool, and fluconazole is a common first-line antifungal treatment for moderate to severe infections.

Conclusions:

• Coccidioidomycosis diagnosis relies heavily on serological testing.
• Antifungal treatment, particularly fluconazole, is crucial for moderate to severe cases.
• Currently, no definitive prevention exists, emphasizing protective measures and education for high-risk populations.